GALANIN REMOLDELING IN THE PROGRESSION OF AD

AD 进展过程中的甘丙肽重塑

基本信息

  • 批准号:
    6927754
  • 负责人:
  • 金额:
    $ 38.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-01 至 2010-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): A crucial challenge in dementia research today is to understand the neurobiologic mechanisms underlying the degenerative and regenerative events which occur during the progression of Alzheimer's disease (AD). This PPG component will examine a set of hypotheses aimed at gaining greater insight into the galaninergic neural remodeling response associated with the survival of cholinergic basal forebrain (CBF) neurons in AD. Recent findings have led us to hypothesize that increased GAL may be neuroprotective for select CBF neurons since neural degeneration is least in the anterior CBF where GAL remodeling occurs, the loss of CBF neurons is minimal in people with mild cognitive impairment (MCI) and mild AD (50) at a point in the disease process where GAL remodeling begins (see Preliminary data), there is a 35% reduction in CBF neurons in the anterior CBF in mice lacking the GAL gene, GAL enhances neurite outgrowth in cultured sensory neurons and GAL and GAL receptors are expressed in embryonic stem cells suggesting a role in cell differentiation. The present application tests a series of hypotheses that during the transition from MCI to AD that 1) GAL remodeling enhances the expression of genes associated with neuroprotection, in anterior CBF neurons including nerve growth factor and its receptors and specific GAL receptor genes; 2) Selectively stabilizes the expression of genes associated with micortublular formation in CBF neurons containing site-specific tau phosphorylation epitopes using antibodies against site-specific tau phosphopeptides provided by Dr. Binder (Project 4); 3) GAL remodeling is associated with an increase in the number of GAL mRNA expressing neurons as AD progresses or alternatively there is an increase in GAL mRNA synthesis per anterior CBF neuron during disease progression, 4; There is an increase in GAL synaptic-like appositions upon anterior CBF hyper innervated neurons using a confocal microscope. GAL remodeling will be evaluated in individuals derived from the Rush Religious Orders Study with a clinical diagnosis of no cognitive impairment, MCI, and AD. The molecular findings will be correlated with cognitive (i.e., declarative, working and episodic memory), attention tests, pathology (i.e., Braak and Reagan Criteria, plaque load) and diagnostic categories. These investigations will lead to novel pharmacological treatments aimed at slowing the relentless onslaught of AD. Summary of the Project 3 Discussion: The revised application is seen as an improvement. There is a consensus that the reviewers recognized the work of Project 3 remains correlative, since no mechanistic investigations are planned; indeed, they may not even be possible when limiting the plan to study of human patient material. Aim 1 was viewed as the most interesting aspect of Project 3. For Aim 2, reviewers strongly urged the PL to include the development of probes to the three galanin receptors for use in the in situ hybridization studies. The sequences are known such that oligonucleotide probes can be as easily prepared as the plan for development of probes for galanin mRNA. A good deal of valuable information could be derived from their use.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ELLIOTT Jay MUFSON其他文献

ELLIOTT Jay MUFSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ELLIOTT Jay MUFSON', 18)}}的其他基金

Default mode network dysfunction in Down Syndrome
唐氏综合症的默认模式网络功能障碍
  • 批准号:
    10635582
  • 财政年份:
    2023
  • 资助金额:
    $ 38.27万
  • 项目类别:
FOREBRAIN NEUROTROPIC ABNORMALITIES & MILD COGNITIVE IMPAIRMENT IN THE ELDERLY
前脑神经营养异常
  • 批准号:
    6299385
  • 财政年份:
    2000
  • 资助金额:
    $ 38.27万
  • 项目类别:
GALANIN REMODELING IN THE PROGRESSION OF ALZHEIMER'S DISEASE
阿尔茨海默病进展中的甘丙肽重塑
  • 批准号:
    6299298
  • 财政年份:
    2000
  • 资助金额:
    $ 38.27万
  • 项目类别:
GALANIN REMODELING IN THE PROGRESSION OF ALZHEIMER'S DISEASE
阿尔茨海默病进展中的甘丙肽重塑
  • 批准号:
    6098278
  • 财政年份:
    1999
  • 资助金额:
    $ 38.27万
  • 项目类别:
Basic Neuroscience Training in Age-Related Disorders
年龄相关疾病的基础神经科学培训
  • 批准号:
    8451416
  • 财政年份:
    1999
  • 资助金额:
    $ 38.27万
  • 项目类别:
FOREBRAIN NEUROTROPIC ABNORMALITIES & MILD COGNITIVE IMPAIRMENT IN THE ELDERLY
前脑神经营养异常
  • 批准号:
    6098740
  • 财政年份:
    1999
  • 资助金额:
    $ 38.27万
  • 项目类别:
Basic Neuroscience Training in Age-Related Disorders
年龄相关疾病的基础神经科学培训
  • 批准号:
    8874078
  • 财政年份:
    1999
  • 资助金额:
    $ 38.27万
  • 项目类别:
GALANIN REMODELING IN THE PROGRESSION OF ALZHEIMER'S DISEASE
阿尔茨海默病进展中的甘丙肽重塑
  • 批准号:
    6295529
  • 财政年份:
    1999
  • 资助金额:
    $ 38.27万
  • 项目类别:
Basic Neuroscience Training in Age-Related Disorders
年龄相关疾病的基础神经科学培训
  • 批准号:
    8658784
  • 财政年份:
    1999
  • 资助金额:
    $ 38.27万
  • 项目类别:
FOREBRAIN NEUROTROPIC ABNORMALITIES & MILD COGNITIVE IMPAIRMENT IN THE ELDERLY
前脑神经营养异常
  • 批准号:
    6267724
  • 财政年份:
    1998
  • 资助金额:
    $ 38.27万
  • 项目类别:

相似国自然基金

肠道菌群介导的脱氧胆酸激活S1PR2/NLRP3/IL-1β通路在炎症性肠病合并艰难梭菌感染中的致病机制研究
  • 批准号:
    82372306
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
噬菌体靶向肠道粪肠球菌提高帕金森病左旋多巴疗效的机制研究
  • 批准号:
    82371251
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
  • 批准号:
    82372073
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
DJ-1与Calnexin互作调控线粒体—内质网联络区参与帕金森病病理机制的研究
  • 批准号:
    82371414
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
藤黄科植物中多靶点抗痴呆症天然先导化合物及其作用机制研究
  • 批准号:
    31770379
  • 批准年份:
    2017
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

Stress Granule Formation in the Antiretroviral-Mediated Dysregulation of Oligodendrocyte Maturation in HIV-HAND
HIV-HAND 中抗逆转录病毒介导的少突胶质细胞成熟失调中的应激颗粒形成
  • 批准号:
    10762118
  • 财政年份:
    2023
  • 资助金额:
    $ 38.27万
  • 项目类别:
Elucidating endolysosomal trafficking dysregulation induced by APOE4 in human astrocytes
阐明人星形胶质细胞中 APOE4 诱导的内溶酶体运输失调
  • 批准号:
    10670573
  • 财政年份:
    2023
  • 资助金额:
    $ 38.27万
  • 项目类别:
Axonal TDP-43 Dysregulation in ALS and Dementia
ALS 和痴呆症中的轴突 TDP-43 失调
  • 批准号:
    10727012
  • 财政年份:
    2023
  • 资助金额:
    $ 38.27万
  • 项目类别:
Role of the microglial immune-oxysterol 25-hydroxycholesterol in mediating neuroinflammation and neurodegeneration in the P301S tau transgenic mouse model of Alzheimer's disease
小胶质细胞免疫-氧甾醇25-羟基胆固醇在阿尔茨海默病P301S tau转基因小鼠模型中介导神经炎症和神经变性中的作用
  • 批准号:
    10645467
  • 财政年份:
    2023
  • 资助金额:
    $ 38.27万
  • 项目类别:
Investigating physiologic and pathophysiologic connections between the Parkinson's disease protein alpha-synuclein and RNA binding proteins
研究帕金森病蛋白 α-突触核蛋白和 RNA 结合蛋白之间的生理和病理生理联系
  • 批准号:
    10744556
  • 财政年份:
    2023
  • 资助金额:
    $ 38.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了